Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) has provided a corporate update and strategic roadmap highlighting advancements in its barium and iodine contrast media projects. The company is focused on addressing critical supply chain vulnerabilities in the diagnostic imaging sector, where demand is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur's strategy involves creating a secure, reliable, and vertically integrated supply chain for both barium and iodine active pharmaceutical ingredients.
Voyageur is currently focused on completing two bankable feasibility studies (BFS) for the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. These projects represent foundational steps toward establishing a resilient, North American–based supply chain. The Frances Creek (FC) barium contrast project is now in the BFS phase, hosting an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate. Recent testing confirms the FC barite purity exceeds 97.5%, with an average grade of 98.8% BaSO4, as detailed in a March 4, 2026 news release. Voyageur has completed product development initiatives for five Health Canada approved barium products with Alberta Veterinary Laboratories and has generated approximately C$32,000 in initial contrast product sales.
FDA regulatory pathways for barium and iodine contrast media are expected to follow an 18 to 24-month review and approval process, potentially enabling U.S. barium market entry as soon as mid-2027 to late 2027. Voyageur has completed the first drafts of all barium FDA submission documents and formally commenced the approval process in February 2026 via the 505(b)(2) regulatory pathway. The review process is anticipated to take approximately one year, with product testing projected at six to seven months. Building on this momentum, Voyageur plans to advance a generic iodine FDA license in the second half of 2026.
Voyageur is independently advancing a prefeasibility study for iodine contrast media drug production, integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. The project leverages iodine-rich brine sourced from oil and gas operations in the United States, targeting 35 million doses per year of iodine contrast drug production. The Bayer Iodine project, backed by a US$2.35M funding arrangement, focuses on completing a BFS. Subject to successful completion, Bayer and Voyageur may advance the project under an offtake-linked production financing arrangement, with Bayer providing capital financing and Voyageur operating and managing the project. This collaboration began with the signing of an LOI with Bayer on December 20, 2024.
Voyageur is engaging with a global engineering company to complete the final two BFS, positioning the company to establish a secure, large-scale, North American supply of essential contrast media drugs. Upon completion, Voyageur will finalize the economics and plant design to vertically produce iodine and barium contrast media drugs, becoming the only vertically integrated radiology drug company in the marketplace. The company is targeting construction to commence in 2027, aiming to provide affordable and secure supplies for healthcare authorities worldwide.
